Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
- Cowen and Company 36th Annual Health Care Conference on March 8 in Boston
- Raymond James 37th Annual Institutional Investors Conference on March 9 in Orlando
- Barclays Global Healthcare Conference on March 16 in Miami
SAN RAFAEL, Calif., March 03, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Cowen and Company 36th Annual Health Care Conference on March 8, 2016 at 8:40am ET in Boston. Management will also participate in the Raymond James 37th Annual Institutional Investors Conference on March 9, 2016 in Orlando and the Barclays Global Healthcare Conference on March 16, 2016 in Miami. To access the live webcasts, please visit the investor section of the BioMarin website, www.BMRN.com. A replay will also be archived on the site for at least one week following the event.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
